Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheumatoid arthritis. Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.
- Ponto de atenção: longer.
- Ponto de atenção: persistence.
- Ponto de atenção: seen.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
